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Introduction 
For oral drug administration, it can be necessary to introduce drug delivery systems to 
facilitate an improvement in bioavailability. Micro fabricated devices have been proposed as 
promising oral drug delivery systems1. Microcontainers are polymeric, cylindrical devices in 
the micrometer size range. They allow for unidirectional release, and the drug can be 
protected inside the cavity of the microcontainer until release is desirable2. 
 
Aim   
The purpose of this study was to investigate interactions between the microcontainers and 
the small intestine in situ and furthermore, to evaluate the oral in vivo performance in rats 
of the microcontainers filled with amorphous sodium salt of furosemide (ASSF). 
 
Method 
Microcontainers (diameter of 223 µm) were fabricated in SU-8 (Fig 1a). The microcontainers 
were filled with ASSF, and the cavity was spray coated with Eudragit L100 or chitosan. In situ 
intestinal perfusions were performed in rats3. The microcontainers were dosed to the small 
intestine, and at the end of the study, the small intestine was harvested from the rat and 
imaged under microscope. For the in vivo studies, the rats were dosed orally with capsules 
containing drug-filled microcontainers coated with Eudragit L100. As control, capsules were 
filled with the powder of ASSF and the capsules were coated with Eudragit L100.  
 
Results   
The microscope images of the small intestine after the perfusion studies showed that the 
microcontainers interacted with the mucus in the small intestine, and the microcontainers 
were engulfed by the intestinal mucus (Fig 1b). The oral bioavailability study showed that 
the relative oral bioavailability of ASSF in microcontainers was found to be 220±43% when 
comparing to drug-filled capsules coated with Eudragit (Fig 1c).   
 
 
Conclusion 
Microcontainers show considerable potential as a future oral drug delivery system. 
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a) b) c) Fig 1 a) SU-8 microcontainer with a 
diameter of 223 µm. b) Microcontainer in 
intestinal mucus following in situ intestinal 
perfusion. c) Plasma concentrations of 
microcontainers filled with ASSF coated 
with Eudragit L100 and filled into capsules 
and ASSF dosed in capsules with Eudragit 
coating after orally dosing to rats 
